Global Information
회사소개 | 문의 | 비교리스트

세계의 비대형 심근증(HCM) 치료제 시장(2020-2026년)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949666
페이지 정보 영문
가격
US $ 3,600 ₩ 4,254,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,672,000 Printable PDF (Enterprise License)


세계의 비대형 심근증(HCM) 치료제 시장(2020-2026년) Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 비대형 심근증(HCM) 치료제 시장은 예측 기간 중 성장이 침체될 것으로 예상됩니다. 심장병에 관한 인식의 향상은 시장의 성장에 기여하고 있습니다. CVD의 건강에 관한 인식을 높이기 위한 정부 구상은 심근증의 진단과 치료의 증가로 연결되고 있습니다. CVD의 예방과 관리에 대해 사람들을 인식시키기 위해 몇개의 계발 프로그램이 개시되었습니다. 예를 들면 2004년에 미국심장협회는 여성의 CVD 예방, 진단, 관리 를 위해 Go Red for Women 캠페인으로 불리는 국제적인 인식 캠페인을 개시했습니다. 이 유형의 구상에 의해 심근증에 관한 인식이 증가하며, CVD의 조기진단으로 연결됩니다. 이것은 다음에 심장이 혈류를 개선할 수 있는 심박수를 감소시키기 위해 HCM 약물 요법의 수요를 지원할 것으로 예상됩니다. 그러나 심장 수술에 대한 새로운 수요는 주로 시장의 성장을 제한하고 있습니다.

지역적으로 아시아태평양은 CVD의 유병률 증가와 정부에 의한 병상의 예방, 진단, 치료에 대한 관심의 증가에 의해 예측 기간 중 대폭적인 성장을 보일 것으로 추정되고 있습니다. HCM은 중국 및 인도를 포함한 아시아태평양 국가에서 유병률의 증가를 목격하고 있는 가장 일반적인 유전성 심질환입니다. 이것은 증상을 관리하고, 돌연사를 막기 위한 약의 수요를 촉진합니다.

세계의 비대형 심근증(HCM) 치료제 시장에 대해 조사했으며, 시장의 개요와 약제 클래스별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재의 시장 동향
  • 룰과 규칙

제3장 경쟁 구도

  • 회사 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • AstraZeneca plc
    • ANI Pharmaceuticals, Inc.
    • MyoKardia, Inc.
    • Bayer AG
    • Sanofi S.A.

제4장 시장 결정요인

  • 동기
  • 억제요인
  • 시장 기회

제5장 시장 세분화

  • 약제 클래스별 세계의 비대형 심근증(HCM) 치료제 시장
    • 베타 아드레날린 차단제
    • 항응고제
    • 항부정맥약
    • 칼슘통로차단제
    • 기타

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • A. Menarini Farmaceutica Internazionale srl
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • General Electric Co.
  • Gilead Sciences, Inc.
  • Lannett Co., Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MyoKardia, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
KSA 20.08.12

LIST OF TABLES

  • 1. GLOBAL HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 2. GLOBAL BETA-ADRENERGIC BLOCKING AGENTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ANTICOAGULANTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANTIARRHYTHMIC AGENTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL CALCIUM CHANNEL BLOCKERS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER HCM THERAPEUTICS DRUG CLASSES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 8. NORTH AMERICAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 9. NORTH AMERICAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 10. EUROPEAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 11. EUROPEAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 12. ASIA-PACIFIC HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. ASIA-PACIFIC HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. REST OF THE WORLD HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HCM THERAPEUTICS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 2. GLOBAL HCM THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share & Trends Analysis Report, By Drug Class (Beta Adrenergic Blocking Agents, Anticoagulants, Antiarrhythmic Agents, Calcium Channel Blockers, and Others) and Forecast, 2020-2026

The global hypertrophic cardiomyopathy (HCM) therapeutics market is expected to witness sluggish growth during the forecast period. Rising awareness regarding heart diseases is contributing to market growth. The government initiatives to increase awareness regarding CVD health is leading to an increasing diagnosis and treatment of the condition. There are several awareness programs launched to make aware people regarding prevention and control of CVD. For instance, in 2004, the American Heart Association launched an international awareness campaign, referred to as Go Red for Women campaign, for the prevention, diagnosis and control of CVD in women. These kinds of initiatives enable to increase awareness about the conditions, leading to an early diagnosis of CVD. This, in turn, is expected to drive the demand for HCM medications to decrease heart rate that enables the heart to pump blood better. However, emerging demand for cardiac surgeries is primarily restricting the growth of the market.

Geographically, Asia-Pacific is estimated to witness significant growth during the forecast period owing to the increasing prevalence of CVD and increasing government focus towards prevention, diagnosis, and treatment of the condition. HCM is the most common inherited cardiac disease that has been witnessing increasing prevalence in Asia-Pacific countries, including China and India. This, in turn, will encourage the demand for medications to control symptoms and prevent sudden death.

Key players in the market include AstraZeneca plc, ANI Pharmaceuticals, Inc., MyoKardia, Inc., Bayer AG, and Sanofi S.A. ANI Pharmaceuticals offers InnoPran XL, Inderal LA, and Inderal XL, that are used for the treatment of HCM. InnoPran XL is a class of medications referred to as beta-adrenergic blocker, designed to treat hypertension, to lower blood pressure. The reduction in blood pressure minimizes the risk of fatal and non-fatal CVD events, particularly myocardial infarction and strokes. Further, MyoKardia, Inc., mavacamten is in Phase II for the treatment of obstructive HCM.

Research Methodology

The market study of the global HCM therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global HCM Therapeutics Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global HCM therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global HCM therapeutics market.
  • Insights about market determinants, which are stimulating the global HCM therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. ANI Pharmaceuticals, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. MyoKardia, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Bayer AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sanofi S.A.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global HCM Therapeutics Market by Drug Class
    • 5.1.1. Beta Adrenergic Blocking Agents
    • 5.1.2. Anticoagulants
    • 5.1.3. Antiarrhythmic Agents
    • 5.1.4. Calcium Channel Blockers
    • 5.1.5. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. A. Menarini Farmaceutica Internazionale srl
  • 7.2. ANI Pharmaceuticals, Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Bristol Myers Squibb Co.
  • 7.6. Cipla Ltd.
  • 7.7. General Electric Co.
  • 7.8. Gilead Sciences, Inc.
  • 7.9. Lannett Co., Inc.
  • 7.10. Merck & Co., Inc.
  • 7.11. Mylan N.V.
  • 7.12. MyoKardia, Inc.
  • 7.13. Novartis International AG
  • 7.14. Pfizer Inc.
  • 7.15. Sanofi S.A.
Back to Top
전화 문의
F A Q